A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Jin, Guang Zhi ^a   Dong, Hui ^a   Yu, Wen Long ^a   Li, Yan ^b   Lu, Xin Yuan ^a   Yu, Hua ^a   Xian, Zhi Hong ^a   Dong, Wei ^a   Liu, Yin Kun ^b   Cong, Wen Ming ^a   Wu, Meng Chao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Aminoacylase 1; Glypican 3; High grade dysplastic nodules; Sequestosome 1; Well differentiated hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; AMINOACYLASE; GLYPICAN 3; SEQUESTOSOME 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HIGH GRADE DYSPLASTIC NODULE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LOW GRADE DYSPLASTIC NODULE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SMALL WELL DIFFERENTIATED HEPATOCELLULAR CARCINOMA; SURVIVAL PREDICTION; SURVIVAL TIME; TUMOR RECURRENCE; VALIDITY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMIDOHYDROLASES; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; NEOPLASM GRADING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875355529     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-161     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005, 25(1):16-27. 10.1111/j.1478-3231.2005.01016.x, 15698394.
3. Hussain SM, Zondervan PE, JN IJ, Schalm SW, de Man RA, Krestin GP. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 2002, 22(5):1023-1036.
4. Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M, Imaoka S. Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 1996, 111(2):455-461. 10.1053/gast.1996.v111.pm8690212, 8690212.
5. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31(4):339-346. 10.1038/ng0802-339, 12149612.
6. de Ledinghen V, Laharie D, Lecesne R, Le Bail B, Winnock M, Bernard PH, Saric J, Couzigou P, Balabaud C, Bioulac-Sage P. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002, 14(2):159-165. 10.1097/00042737-200202000-00010, 11981340.
7. Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers. Intervirology 2004, 47(3-5):191-198.
8. Roncalli M, Roz E, Coggi G, Di Rocco MG, Bossi P, Minola E, Gambacorta M, Borzio M. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999, 30(5):1174-1178. 10.1002/hep.510300507, 10534338.
9. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003, 37(1):198-207. 10.1053/jhep.2003.50022, 12500205.
10. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45(3):725-734. 10.1002/hep.21531, 17326147.
11. Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM, Chu PG. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 2008, 32(3):433-444. 10.1097/PAS.0b013e318158142f, 18300806.
12. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125(1):89-97. 10.1016/S0016-5085(03)00689-9, 12851874.
13. Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, Iavarone M, Colombo M, Jang JJ, Yu E. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009, 50(4):746-754. 10.1016/j.jhep.2008.11.014, 19231003.
14. Tatrai P, Somoracz A, Batmunkh E, Schirmacher P, Kiss A, Schaff Z, Nagy P, Kovalszky I. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions. Am J Surg Pathol 2009, 33(6):874-885. 10.1097/PAS.0b013e318194b3ea, 19194276.
15. Jin GZ, Li Y, Cong WM, Yu H, Dong H, Shu H, Liu XH, Yan GQ, Zhang L, Zhang Y. iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J Proteome Res 2011, 10(8):3418-3428. 10.1021/pr200482t, 21631109.
16. Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y, Fang-yin Z, Da-yong Z, Rong-cheng L. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep 2012, 39(1):351-357. 10.1007/s11033-011-0745-y, 21655958.
17. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009, 100(8):1403-1407. 10.1111/j.1349-7006.2009.01206.x, 19496787.
18. Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, Ohtomo T, Nagaike K, Kondo K, Chijiiwa K. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int 2010, 31(1):120-131.
19. Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, Chen MF, Tsai CN. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol 2011, Epub ahead of print.
20. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009, 49(2):658-664.
21. Bosman FT CF, Hruban RH. WHO Classification of tumours of the digestive system 2010, 205-216. Lyon: IARC Press, 4.
22. Sobin LH WC. TNM classification of malignant tumors 2002, 81-83. New York: Wiley-Liss, 6.
23. Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, Matthews J, Norton AJ, Gribben JG, Lister TA. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006, 24(31):5052-5059. 10.1200/JCO.2006.06.4642, 17033038.
24. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008, 26(16):2707-2716. 10.1200/JCO.2007.15.6521, 18509183.
25. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008, 100(20):1432-1438. 10.1093/jnci/djn326, 2567415, 18840817.
26. Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, Venturi AM, Piscaglia F. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005, 42(1):27-34. 10.1002/hep.20728, 15954118.
27. Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl 2004, 10(2 Suppl 1):S3-S8.
28. Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 2011, 60(7):967-976. 10.1136/gut.2010.231993, 21330577.
29. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006, 30(11):1405-1411. 10.1097/01.pas.0000213323.97294.9a, 17063081.
30. Di Tommaso L, Destro A, Fabbris V, Spagnuolo G, Laura Fracanzani A, Fargion S, Maggioni M, Patriarca C, Maria Macchi R, Quagliuolo M. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011, 53(5):1549-1557. 10.1002/hep.24218, 21520170.
31. Gade W, Brown JL. Purification, characterization and possible function of alpha-N-acylamino acid hydrolase from bovine liver. Biochim Biophys Acta 1981, 662(1):86-93. 10.1016/0005-2744(81)90227-8, 7306559.
32. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, Birkenbach M. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996, 70(2):1143-1153. 189923, 8551575.
33. Wooten MW, Seibenhener ML, Mamidipudi V, Diaz-Meco MT, Barker PA, Moscat J. The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor. J Biol Chem 2001, 276(11):7709-7712. 10.1074/jbc.C000869200, 11244088.
34. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 1999, 18(11):3044-3053. 10.1093/emboj/18.11.3044, 1171386, 10356400.
35. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-777. 10.1146/annurev.biochem.68.1.729, 10872465.
36. Davoodi J, Kelly J, Gendron NH, MacKenzie AE. The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics 2007, 7(13):2300-2310. 10.1002/pmic.200600654, 17549790.
37. Okamoto N, Yagi M, Imura K, Wada Y. A clinical and molecular study of a patient with Simpson-Golabi-Behmel syndrome. J Hum Genet 1999, 44(5):327-329. 10.1007/s100380050170, 10496077.
38. Lin Q, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY, Chen M. Expression of GPC3 protein and its significance in lung squamous cell carcinoma. Med Oncol 2012, 29(2):663-669. 10.1007/s12032-011-9973-1, 21556932.
39. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000, 31(4):302-308. 10.1097/00004836-200012000-00007, 11129271.
40. Xu YF, Yi Y, Qiu SJ, Gao Q, Li YW, Dai CX, Cai MY, Ju MJ, Zhou J, Zhang BH. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. J Hepatol 2010, 53(5):872-879. 10.1016/j.jhep.2010.05.019, 20739083.